

Appl. No.  
Filed

: 09/350,043  
: July, 8, 1999

Sub B1  
Contd  
A1  
Cont

an ethoxylated lipid;  
an alcohol mixed with the ethoxylated lipid so as to form a penetration enhancer;  
an aqueous adjuvant mixed with the penetration enhancer, wherein the aqueous adjuvant comprises *Aloe Vera*, and  
a delivery agent mixed with the aqueous adjuvant and the penetration enhancer.

2. (AMENDED) The transdermal delivery system of Claim 1, wherein the ethoxylated lipid is a vegetable or animal oil having at least 20 ethoxylations per molecule.

A2

5. (AMENDED) The transdermal delivery system of Claim 1, wherein about 0.1% to 85% by weight or volume is *Aloe Vera*.

A3

9. (AMENDED) The transdermal delivery system of Claim 1, wherein the delivery agent is selected from the group consisting of capsaicin, Boswellin, non steroidal anti-inflammatory drug, and collagen.

A4  
Sub B2

12. (AMENDED) A transdermal delivery system comprising:  
an ethoxylated oil;  
an alcohol mixed with the ethoxylated oil so as to form a penetration enhancer;  
*Aloe Vera* mixed with the penetration enhancer; and  
a therapeutically effective amount of capsaicin or NSAID or both mixed with the penetration enhancer and *Aloe Vera*.

17. (CANCELLED)

18. (CANCELLED)

Sub B3  
AS

19. (AMENDED) A transdermal delivery system comprising:  
an ethoxylated oil;

Appl. No. : 09/350,043  
Filed : July, 8, 1999

Sub B3  
cont'd

AS  
cont

an alcohol mixed with the ethoxylated oil so as to form a penetration enhancer;  
an aqueous adjuvant mixed with the penetration enhancer, wherein the aqueous  
adjuvant comprises *Aloe Vera*; and  
a therapeutically effective amount of a delivery agent having a molecular weight  
of more than 2,000 daltons mixed with the penetration enhancer and aqueous adjuvant.

20. (CANCELLED)

29  
21. (AMENDED) The transdermal delivery system of Claim <sup>28</sup>~~19~~, wherein the delivery agent  
is a collagen or fragment thereof.

30  
22. (AMENDED) The transdermal delivery system of Claim <sup>29</sup>~~21~~, wherein the collagen has an  
approximate average molecular weight from about 2,000 daltons to about 500,000 daltons.

31  
23. (AMENDED) The transdermal delivery system of Claim <sup>29</sup>~~21~~, wherein the therapeutically  
effective amount of collagen by weight or volume is 0.1% to 50.0%.

32  
24. (AMENDED) The transdermal delivery system of Claim <sup>29</sup>~~21~~, wherein the collagen has an  
approximate average molecular weight of about 2,000 daltons and the therapeutically effective  
amount by weight or volume is 0.1% to 50.0%.

33  
25. (AMENDED) The transdermal delivery system of Claim <sup>29</sup>~~21~~, wherein the collagen has an  
approximate average molecular weight of about 300,000 daltons and the therapeutically effective  
amount is 0.1% to 2.0%.

34  
26. (AMENDED) The transdermal delivery system of Claim <sup>29</sup>~~21~~, wherein the collagen has an  
approximate average molecular weight of about 500,000 daltons and the therapeutically effective  
amount by weight or volume is 0.1% to 4.0%.

Appl. No. : 09/350,043  
Filed : July, 8, 1999

29. (CANCELLED)

30. (AMENDED) A method of making a transdermal delivery system comprising:  
providing an ethoxylated oil;  
mixing the ethoxylated oil with an alcohol, nonionic solubilizer, or emulsifier so  
as to form a penetration enhancer;  
mixing the penetration enhancer with an aqueous adjuvant, wherein the aqueous  
adjuvant comprises *Aloe Vera*; and  
mixing the penetration enhancer and aqueous adjuvant with a delivery agent and  
thereby making the transdermal delivery system.

32. (AMENDED) The method of Claim 30, wherein the delivery agent has a molecular  
weight greater than 2,000 daltons.

35. (NEW) The transdermal delivery system of Claim 1, wherein the delivery agent is a non  
steroidal anti-inflammatory drug.

36. (NEW) The transdermal delivery system of Claim 35, wherein the non steroidal anti-  
inflammatory drug is selected from the group consisting of naproxin, ibuprofen, and aspirin.

37. (NEW) The transdermal delivery system of Claim 35, wherein the non steroidal anti-  
inflammatory drug is aspirin.